AstraZeneca says it will withdraw COVID-19 vaccine globally
New Delhi: The vaccine most consumed in India, will soon disappear from the drug shelves of the country as AstraZeneca on Tuesday announced it had initiated the worldwide withdrawal of its COVID 19 vaccine due to a ''surplus of available updated vaccines'' since the pandemic.
The UK-based pharmaceutical company in collaboration with the Serum Institute of India (SII), the world's largest vaccine manufacturer, had made available the Covishield vaccine to the Indian population .
AstraZeneca, which partnered with the University of Oxford to develop the vaccine, is now facing a lawsuit alleging that the vaccine resulted in deaths and serious injuries to recipients.
Also Read:AstraZeneca admits 'very rare' side effect of COVID vaccine in UK court
However, the company has cited commercial reasons for the withdrawal as "surplus of available updated vaccines"
The company also said it would proceed to withdraw the vaccine Vaxzevria's marketing authorizations within Europe.
"As multiple, variant COVID-19 vaccines have since been developed there is a surplus of available updated vaccines," the company said, adding that this had led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied.
The Anglo-Swedish drugmaker has previously admitted in court documents that the vaccine causes side-effects such as blood clots and low blood platelet counts.
The firm's application to withdraw the vaccine was made on March 5 and came into effect on May 7, according to the Telegraph, which first reported the development.
Medical Dialogues had earlier reported that the pharmaceutical giant is being sued in a class action in UK over claims that its vaccine against Covid-19, developed with the University of Oxford, caused death and serious injury, including TTS — Thrombosis with Thrombocytopenia Syndrome — which causes people to have blood clots and a low blood platelet count. In India as well, a plea was submitted to the Supreme Court last week , urging the establishment of a medical expert panel overseen by a retired apex court judge. This panel would be tasked with assessing potential side effects and risk factors associated with the Covishield vaccine.
Also Read:Plea in SC seeking expert panel to examine possible side effects, risk factors of Covishield
London-listed AstraZeneca began moving into respiratory syncytial virus vaccines and obesity drugs through several deals last year after a slowdown in growth as COVID-19 medicine sales declined.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.